---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-061079"
form_type: "8-K/A"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2024-05-16T23:59:59+00:00"
generated_at: "2026-06-01T21:25:39.500756+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Prelude Therapeutics grants 25,000 stock options to Interim CFO Bryant D. Lim

## Summary
- Options to purchase 25,000 shares of common stock at $3.86 per share.
- Options vest over 4 years (25% at 1 year, then monthly); 10-year term.
- Grant approved by Compensation Committee on May 14, 2024, under 2020 Equity Incentive Plan.
- Amendment to prior 8-K reporting Lim's appointment as Interim CFO.

## SEC filing metadata
- accession: 0000950170-24-061079
- form_type: 8-K/A
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2024-05-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000095017024061079/0000950170-24-061079-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000095017024061079/prld-20240408.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-061079
- JSON: https://secwatch.observer/filing/0000950170-24-061079.json
- Plain text: https://secwatch.observer/filing/0000950170-24-061079.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.